LABRADIMIL, a synthetic bradykinin analog, is a potent bradykinin B2 receptor agonist. It increases vascular permeability by the activation of B2 receptors on the vascular endothelium. It also selectively increases uptake of molecular tracers in brain tumors.

SPK-843 is a water-soluble partricin derivative patented by SPA Societa Prodotti Antibiotici S.p.A. and developed by Aparts and Kaken for the potential treatment of systemic fungal infections. In preclinical models, SPK-843 shows in vitro inhibitory activity comparable to or better than that of Amphotericin B against Candida spp., Cryptococcus neoformans, and Aspergillus spp. SPK-843 exhibits dose-dependent efficacy on murine pulmonary aspergillosis models. SPK-843 doses of higher than 1.0 mg/kg of body weight exhibit no renal toxicities and a tendency toward better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone) and liposomal amphotericin B.

Galamustine (C6-galactose mustard or C6-GLM ) is a compound that has demonstrated anti-cancer activity. Its effect on cell growth and cell cycle kinetics was studied in leukemia. Because less bone marrow toxicity was reported for this compound compared to nitrogen mustard, the development of galamustine for clinical trials in humans was considered.